Peroxisome proliferator-activated receptor &gamma; agonist reduces the severity of post-ERCP pancreatitis in rats

doi:10.3748/wjg.v12.i40.6458

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 40

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2298)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

304

HTML

1848

Figures (1-7)

146

Sum=2298

Oct 28, 2006 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Oct 28, 2006; 12(40): 6458-6463
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6458

Full Size Figure Download Figure

Figure 5 Myeloperoxidase activity in pancreas. MPO activity was significantly increased in post-ERCP induced pancreatitis in comparison with vehicle. Rosiglitazone treatment prevented this increase. ^aP < 0.05 AP vs control; ^cP < 0.05 rosiglitazone-treated AP group vs Vehicle-treated AP group.

Citation: Folch-Puy E, Granell S, Iovanna JL, Barthet M, Closa D. Peroxisome proliferator-activated receptor γ agonist reduces the severity of post-ERCP pancreatitis in rats. World J Gastroenterol 2006; 12(40): 6458-6463
URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6458.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6458